ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This is in contrast to the experience in cancer therapy where small molecule-based targeted therapies (such as BCR-Abl inhibitors) have been used successfully for the treatment of chronic myeloid leukemia and other hematological malignancies.